Innate Pharma SA (IPHA) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 11 institutional investors hold a position in Innate Pharma SA (NASDAQ:IPHA).

• Innate Pharma saw its institutional ownership percentage rose to 0.3% in December 2025 from 0.1% in September 2025.
• Quarterly data indicates a 349.74% shift in institutional share volume, and the annual owner count reflects an increase of 10.00%.
• Of these 11 institutional investors, 6 increased their holdings in Innate Pharma, while 4 of them reduced positions, and 1 investors maintained their exposure.
• Collectively, institutional investors increased their stake in Innate Pharma to 276.27K shares as of December 2025, a change that is up by 214.84K shares quarter on quarter and up 138.30K shares year over year.
• As of December 31, 2025, JANE STREET GROUP, LLC held Innate Pharma's largest shareholding position with over 92.75K shares, representing 0.09% of total outstanding shares.
• Among the most significant buyers of Innate Pharma during December 2025 were JANE STREET GROUP, LLC (92.75K), Lion Point Capital, LP (81.15K), OLD MISSION CAPITAL LLC (28.43K), MILLENNIUM MANAGEMENT LLC (20.31K), RHUMBLINE ADVISERS (4.73K).
• Leading sellers of Innate Pharma stock in December 2025 included MORGAN STANLEY (7.17K), UBS Group AG (3.85K), GAMMA Investing LLC (1.21K), BARCLAYS PLC (306).
• The top 10 institutional holders of Innate Pharma for the quarter ending December 2025 included JANE STREET GROUP, LLC (92.75K), Lion Point Capital, LP (81.15K), MORGAN STANLEY (46.39K), OLD MISSION CAPITAL LLC (28.43K), MILLENNIUM MANAGEMENT LLC (20.31K), RHUMBLINE ADVISERS (5.20K), GAMMA Investing LLC (1.07K), UBS Group AG (947), Farther Finance Advisors, LLC (10), BARCLAYS PLC (1).